AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30570315 — intervention group
Group type: EXPERIMENTAL
Intervention: low-intensity mindfulness training
Number of subjects: 125
Study 30570315 — intervention group
Group type: COMPARATOR
Intervention: control group (not specified)
Number of subjects: 125
Study 30570358 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Echogenicity Grade
Number of subjects: 0
Study 30570358 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Echo-Free Space Grade
Number of subjects: 0
Study 30570502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for POP
Number of subjects: 103
Study 30570502 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessments (PFDI-20, PFIQ-7)
Number of subjects: 103
Study 30570502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Severity Scale
Number of subjects: 103
Study 30570502 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessments (PFDI-20, PFIQ-7, PROMIS-57)
Number of subjects: 103
Study 30570526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir CD4 T-cell count
Number of subjects: 223
Study 30570526 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA
Number of subjects: 223
Study 30570526 — intervention group
Group type: EXPERIMENTAL
Intervention: aSMA
Number of subjects: 223
Study 30570526 — intervention group
Group type: EXPERIMENTAL
Intervention: aLKM1
Number of subjects: 223
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg administered intravenously every 3 weeks until disease progression, unacceptable toxic effects, or study withdrawal, for up to 2 years.
Number of subjects: 121
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with ESCC.
Number of subjects: 121
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with adenocarcinoma.
Number of subjects: 121
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with PD-L1-positive tumors.
Number of subjects: 121
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for patients with PD-L1-negative tumors.
Number of subjects: 121
Study 30570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab treatment-related adverse events.
Number of subjects: 121
Study 30570744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat (70 mg 3 times per week escalating to 90 mg TIW)
Number of subjects: 17
Study 30570744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Number of subjects: 17
Study 30570763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab (600 mg maintenance dose)
Number of subjects: 0
Study 30570763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab (1200 mg loading dose)
Number of subjects: 0
Study 30570763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) pertuzumab and trastuzumab (fixed-dose combination)
Number of subjects: 0
Study 30571184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/kg lipopolysaccharide (LPS)
Number of subjects: 40
Study 30571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown experiments in THP-1 monocytes
Number of subjects: 40
Study 30571191 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1175
Study 30571194 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk score
Number of subjects: 2060
Study 30571194 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE-2 (ES2)
Number of subjects: 2060
Study 30571194 — intervention group
Group type: COMPARATOR
Intervention: Contemporary Cohort (CC)
Number of subjects: 2060
Study 30571194 — intervention group
Group type: COMPARATOR
Intervention: STICH cohort
Number of subjects: 2060
Study 30571197 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF (EF ≥45%)
Number of subjects: 202
Study 30571197 — intervention group
Group type: COMPARATOR
Intervention: HFrEF (EF <45%)
Number of subjects: 202
Study 30571200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody valve implantation
Number of subjects: 68
Study 30571203 — intervention group
Group type: EXPERIMENTAL
Intervention: Post chronic total occlusion PCI
Number of subjects: 26
Study 30571203 — intervention group
Group type: COMPARATOR
Intervention: Subintimal recanalization
Number of subjects: 26
Study 30571203 — intervention group
Group type: COMPARATOR
Intervention: Intrapaque recanalization
Number of subjects: 26
Study 30571203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months follow-up
Number of subjects: 26
Study 30571206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 8582
Study 30571206 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 8582
Study 30571323 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in Carotid Temperature Heterogeneity
Number of subjects: 0
Study 30571333 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight variability (measured as average successive variability)
Number of subjects: 6408
Study 30571333 — intervention group
Group type: COMPARATOR
Intervention: Body weight variability (highest quintile vs lowest quintile)
Number of subjects: 6408
Study 30571334 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-Collaborative hospitals (n=33)
Number of subjects: 911754
Study 30571334 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CollaborativeOnly hospitals (n=15)
Number of subjects: 911754
Study 30571334 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CollaborativePlus hospitals (n=18)
Number of subjects: 911754
Study 30571334 — intervention group
Group type: COMPARATOR
Intervention: STS-nonMI hospitals
Number of subjects: 911754
Study 30571347 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway implementation
Number of subjects: 8474
Study 30571347 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation cohort
Number of subjects: 8474
Study 30571400 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 285292
Study 30571400 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 285292
Study 30571400 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 285292
Study 30571492 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weights at ages 20 and 40 years
Number of subjects: 6437
Study 30571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 1171
Study 30571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1171
Study 30571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with high-normal BP
Number of subjects: 1171
Study 30571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with BP in hypertensive range
Number of subjects: 1171
Study 30571553 — intervention group
Group type: COMPARATOR
Intervention: Normotensive peers
Number of subjects: 1171
Study 30571553 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with highest cardiorespiratory fitness
Number of subjects: 1171
Study 30571969 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase 1/11 invalidation or pharmacological inhibition by Ac-YVAD-CMK injection
Number of subjects: 0
Study 30571969 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 30572275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (highest quintile)
Number of subjects: 3300
Study 30572275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (second quintile)
Number of subjects: 3300
Study 30572275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (third quintile)
Number of subjects: 3300
Study 30572275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (fourth quintile)
Number of subjects: 3300
Study 30572275 — intervention group
Group type: COMPARATOR
Intervention: Whole fruit consumption (lowest quintile)
Number of subjects: 3300
Study 30572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE)
Number of subjects: 33
Study 30572352 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS) alone
Number of subjects: 33
Study 30572827 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperemesis gravidarum group
Number of subjects: 40
Study 30572827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 30572830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related delay
Number of subjects: 137
Study 30572830 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-related delay
Number of subjects: 137
Study 30572830 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic delay
Number of subjects: 137
Study 30572830 — intervention group
Group type: COMPARATOR
Intervention: Living in Italy for < 5 years vs > 5 years
Number of subjects: 137
Study 30572830 — intervention group
Group type: COMPARATOR
Intervention: Extra-pulmonary TB
Number of subjects: 137
Study 30572830 — intervention group
Group type: COMPARATOR
Intervention: First contact with general practitioner
Number of subjects: 137
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: FSFI questionnaire
Number of subjects: 50
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: GRISS questionnaire
Number of subjects: 50
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-F questionnaire
Number of subjects: 50
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of FSFI and SQ-F
Number of subjects: 50
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SQ-F and GRISS
Number of subjects: 50
Study 30572853 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of questionnaires
Number of subjects: 50
Study 30572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 426
Study 30572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Face, Legs, Activity, Cry, Consolability (FLACC) Scale
Number of subjects: 426
Study 30572868 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental interview assessment of moderate/severe pain
Number of subjects: 426
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based medication reporting
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based symptoms reporting
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of smartwatch data streaming
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of structured motor tasks at home
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined schedules and app-based reminders
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance rate for HD patients
Number of subjects: 68
Study 30572891 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance rate for PD patients
Number of subjects: 68
Study 30572920 — intervention group
Group type: EXPERIMENTAL
Intervention: Aedes aegypti salivary gland homogenate antibody intensity determinations by ELISA assays
Number of subjects: 771
Study 30572920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serosurveillance for dengue seroconversion
Number of subjects: 771
Study 30572920 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests for acute dengue, Zika, and chikungunya viral infections by RT-PCR
Number of subjects: 771
Study 30572922 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR T cell therapy
Number of subjects: 57
Study 30573441 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote pulse oximetry system
Number of subjects: 105
Study 30573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone support
Number of subjects: 190
Study 30573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support
Number of subjects: 190
Study 30573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives (for nonresponders)
Number of subjects: 190
Study 30573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering of interventions (for responders)
Number of subjects: 190
Study 30573486 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation support from healthcare professionals
Number of subjects: 382
Study 30573486 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of days of hospitalisation admission in the preceding year
Number of subjects: 382
Study 30573486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perceived correlation between smoking and their illness
Number of subjects: 382
Study 30573486 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms experienced during hospitalisation
Number of subjects: 382
Study 30573489 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0
Study 30573489 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study 30573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication treatment
Number of subjects: 363
Study 30573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of psychotropic medication treatment
Number of subjects: 363
Study 30573492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental healthcare utilisation, psychiatric symptomatology, problem behaviour, institutional factors
Number of subjects: 363
Study 30573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with ICE (ifosfamide, carboplatin, etoposide)
Number of subjects: 0
Study 30573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with ICE/R (ifosfamide, carboplatin, etoposide, and rituximab)
Number of subjects: 0
Study 30573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent bortezomib
Number of subjects: 0
Study 30573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 30573690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with dendritic cell (DC) vaccination (ESO cohort)
Number of subjects: 10
Study 30573690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with dendritic cell (DC) vaccination and ipilimumab (INY cohort)
Number of subjects: 10
Study 30573970 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 67
Study 30573970 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 67
Study 30574050 — intervention group
Group type: EXPERIMENTAL
Intervention: EL+MV
Number of subjects: 93
Study 30574327 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 42
Study 30574327 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginners
Number of subjects: 42
Study 30574327 — intervention group
Group type: COMPARATOR
Intervention: All observers
Number of subjects: 42
Study 30574343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (BID)
Number of subjects: 6897
Study 30574516 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-RSI score at preoperative, 4-month, 6-month, 1-year, and 2-year follow-up
Number of subjects: 681
Study 30574516 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to sport (running and the same preinjury sport)
Number of subjects: 681
Study 30574672 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg subcutaneously once every 4 weeks for 12 weeks
Number of subjects: 21
Study 30574833 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 75
Study 30575051 — intervention group
Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using deformable image registration (DIR) methods classified into B-splines, Free-form, Diffeomorphisms, or Biomechanical modeling.
Number of subjects: 50
Study 30575051 — intervention group
Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using various hybrid approaches based on DIR evaluation of volume change, Hounsfield Unit change.
Number of subjects: 50
Study 30575311 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 174
Study 30575311 — intervention group
Group type: COMPARATOR
Intervention: R-galiximab (Anti-CD80)
Number of subjects: 174
Study 30575311 — intervention group
Group type: COMPARATOR
Intervention: R-epratuzumab (Anti-CD22)
Number of subjects: 174
Study 30575311 — intervention group
Group type: COMPARATOR
Intervention: R-lenalidomide
Number of subjects: 174
Study 30576085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg daily
Number of subjects: 75
Study 30576221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-Flow Therapy
Number of subjects: 0
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting methods
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Future pregnancy plans
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Some college education
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Having 2 or more children
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' insurance
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who switched methods
Number of subjects: 2583
Study 30576664 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for stopping
Number of subjects: 2583
Study 30576755 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 30576755 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30576970 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months
Number of subjects: 112
Study 30576970 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 112
Study 30577768 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase contrast (PC) MRI following modest exercise challenge
Number of subjects: 21
Study 30577768 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 30577792 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis (DIE)
Number of subjects: 234
Study 30577792 — intervention group
Group type: COMPARATOR
Intervention: Ovarian endometrioma (OMA)
Number of subjects: 234
Study 30577883 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) questionnaire
Number of subjects: 429
Study 30577883 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not undergo colonoscopy)
Number of subjects: 429
Study 30577927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment for depression (PCIT-ED)
Number of subjects: 314
Study 30577988 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus weekly paclitaxel
Number of subjects: 1
Study 30577988 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy, paclitaxel (70 mg/m2)
Number of subjects: 1
Study 30578023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily, taken orally without food, until progression or intolerance.
Number of subjects: 36
Study 30578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Care based on distance monitoring (G_TECCU)
Number of subjects: 63
Study 30578197 — intervention group
Group type: COMPARATOR
Intervention: Nurse-assisted telephone care (G_NT)
Number of subjects: 63
Study 30578197 — intervention group
Group type: COMPARATOR
Intervention: Standard care (G_Control)
Number of subjects: 63
Study 30578773 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation-focused strategies
Number of subjects: 168
Study 30578773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services
Number of subjects: 168
Study 30578773 — intervention group
Group type: EXPERIMENTAL
Intervention: Having strategies-by-rehabilitation-by-time
Number of subjects: 168
Study 30578773 — intervention group
Group type: EXPERIMENTAL
Intervention: History of a preexisting condition
Number of subjects: 168
Study 30578773 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in functional capacities at PICU discharge
Number of subjects: 168
Study 30579045 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label antidepressant treatment for up to 24 months
Number of subjects: 106
Study 30579270 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) using 124I-8H9, a radioimmunotherapeutic agent, with a mean infusate volume of 3.84-4.54 ml.
Number of subjects: 31
Study 30579270 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) in the highest dose level.
Number of subjects: 31
Study 30579270 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratentorial approach to the brainstem crossing the CST.
Number of subjects: 31
Study 30579270 — intervention group
Group type: EXPERIMENTAL
Intervention: CED with catheter placement-related adverse events.
Number of subjects: 31
Study 30579270 — intervention group
Group type: EXPERIMENTAL
Intervention: CED with Vd-CST overlap analysis.
Number of subjects: 31
Study 30579327 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic tests-guided therapy with synthetic factor concentrates
Number of subjects: 237
Study 30579327 — intervention group
Group type: COMPARATOR
Intervention: Control group (before implementation of protocol)
Number of subjects: 237
Study 30579387 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 80
Study 30579387 — intervention group
Group type: COMPARATOR
Intervention: Conditioned pain modulation assay
Number of subjects: 80
Study 30579407 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative delta power (1-4 Hz) from single-channel EEG
Number of subjects: 159
Study 30579407 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative power from 1 to 6 Hz
Number of subjects: 159